Can an experimental immunotherapy boost the power of standard bladder cancer treatment?
NCT ID NCT07726992
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding an experimental drug called SHR-1501 to the standard BCG therapy can improve outcomes for people with a high-risk form of bladder cancer that has not spread into the muscle wall. Participants must have had all visible tumors removed before starting treatment. The study compares the combination against BCG plus a placebo to see if it extends the time before the cancer returns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental immunotherapy drug called SHR-1501 combined with a standard bladder cancer treatment (BCG)
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with high-risk bladder cancer, potentially reducing the chance of the cancer coming back.
- What could go wrong
- This is an early-phase trial, so the benefits are not yet proven. Adding a new drug may also increase side effects, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PAPILLARY-ONLY NON-MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Medical Center of the Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, 100036, China